Difference between revisions of "Category:BTK inhibitors"
Jump to navigation
Jump to search
m |
m |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | A class of drugs that inhibit Bruton's tyrosine kinase (BTK). The first drug approved in this class is [[Ibrutinib (Imbruvica)]]. | + | A class of drugs that inhibit Bruton's tyrosine kinase (BTK). The first specific drug approved in this class is [[Ibrutinib (Imbruvica)]], although [[Dasatinib (Sprycel)]] has some demonstrated degree of BTK inhibition<ref>[http://www.ncbi.nlm.nih.gov/pubmed/17684099 The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8. Epub 2007 Aug 7.]</ref>. |
| − | [[Category: | + | ==References== |
| + | <references/> | ||
| + | |||
| + | [[Category:Tyrosine kinase inhibitors]] | ||
Latest revision as of 21:55, 22 January 2021
A class of drugs that inhibit Bruton's tyrosine kinase (BTK). The first specific drug approved in this class is Ibrutinib (Imbruvica), although Dasatinib (Sprycel) has some demonstrated degree of BTK inhibition[1].
References
Pages in category "BTK inhibitors"
The following 8 pages are in this category, out of 8 total.